Q2 Earnings Forecast for Progyny Issued By Leerink Partnrs

Progyny, Inc. (NASDAQ:PGNY - Free Report) - Stock analysts at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Progyny in a research note issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.18 per share for the quarter, up from their prior forecast of $0.15. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Progyny's current full-year earnings is $0.60 per share. Leerink Partnrs also issued estimates for Progyny's Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.64 EPS.

Several other equities analysts have also issued reports on PGNY. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a report on Tuesday. Canaccord Genuity Group lowered their target price on shares of Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Finally, BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a research note on Monday, March 31st. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $24.09.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $0.40 during trading on Friday, reaching $23.21. 739,927 shares of the company were exchanged, compared to its average volume of 1,718,762. The firm has a market capitalization of $1.99 billion, a PE ratio of 44.55, a P/E/G ratio of 2.43 and a beta of 1.31. The business's fifty day simple moving average is $21.81 and its 200-day simple moving average is $21.47. Progyny has a 12-month low of $13.39 and a 12-month high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to analysts' expectations of $307.86 million. Progyny had a return on equity of 10.90% and a net margin of 4.33%. The business's revenue was up 16.5% compared to the same quarter last year. During the same period last year, the business posted $0.17 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC increased its holdings in Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Progyny in the first quarter valued at $44,000. Militia Capital Partners LP increased its holdings in Progyny by 100.0% in the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after buying an additional 1,000 shares in the last quarter. Natixis purchased a new position in Progyny in the fourth quarter valued at $69,000. Finally, Brooklyn Investment Group increased its holdings in Progyny by 5,216.4% in the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock valued at $72,000 after buying an additional 3,182 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Progyny

In related news, Director Cheryl Scott sold 2,675 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the transaction, the director directly owned 14,112 shares in the company, valued at $311,451.84. The trade was a 15.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.40% of the stock is owned by corporate insiders.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.